Corcept Therapeutics (CORT) Research & Development (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Research & Development data on file, last reported at $66.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 9.11% year-over-year to $66.3 million; the trailing twelve-month figure through Mar 2026 stood at $260.4 million (up 4.54% YoY), and the FY2025 full-year result was $254.9 million, up 3.25% from the prior year.
• Research & Development advanced to $66.3 million in Q1 2026, from $64.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $70.3 million in Q4 2024 to a low of $28.1 million in Q1 2022.
• A 5-year average of $52.0 million and a median of $58.5 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 48.85% in 2023 and fell 7.74% in 2025, its largest moves.
• Tracing CORT's Research & Development over 5 years: stood at $36.8 million in 2022, then jumped by 48.85% to $54.7 million in 2023, then grew by 28.5% to $70.3 million in 2024, then slipped by 7.74% to $64.9 million in 2025, then advanced by 2.17% to $66.3 million in 2026.
• Business Quant data shows CORT's Research & Development at $66.3 million in Q1 2026, $64.9 million in Q4 2025, and $68.8 million in Q3 2025.